Global Statistics

All countries
163,714,287
Confirmed
Updated on May 16, 2021 9:47 pm
All countries
143,319,369
Recovered
Updated on May 16, 2021 9:47 pm
All countries
3,393,280
Deaths
Updated on May 16, 2021 9:47 pm
Sunday, May 16, 2021

Global Statistics

All countries
163,714,287
Confirmed
Updated on May 16, 2021 9:47 pm
All countries
143,319,369
Recovered
Updated on May 16, 2021 9:47 pm
All countries
3,393,280
Deaths
Updated on May 16, 2021 9:47 pm
Molderizer and Safe Shield

Pfizer Wants The FDA to Approve COVID Vaccine for Those 12 to 15

Coronavirus latest: India export ban leaves global jab supply far behind schedule, says Unicef

Before coronavirus arrived in the UK, only 3.8 per cent of the country’s 812,000 call centre workers were based at home, according to...

Covid-19 Live News Tracker: Global Updates on Vaccines and Cases

Here’s what you need to know:Dr. Rochelle P. Walensky during a Senate Health, Education, Labor and Pensions Committee hearing last week.Credit...Pool photo by...

Coronavirus US: death toll tops 160,000 as relief package impasse continues live updates

More than 6000 British Airways staff have accepted voluntary redundancy as the airline moves to tell thousands more cabin crew and ground staff whether...

Working from home improving mental health of dads much more than moms: study

by: Kevin Torres/KDVR, Nexstar Media Wire Posted: May 16, 2021 / 12:42 PM EDT / Updated: May 16, 2021 / 12:42 PM EDT


Medical syringe is seen with Pfizer company logo displayed on a screen in the background in this illustration photo taken in Poland on November 16, 2020. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

 

Yesterday Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX)  requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) to expand the use in adolescents 12 to 15 years of age. The companies plan to request similar rulings by other regulatory authorities worldwide in coming days. These requests are based on data from the pivotal Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, which demonstrated 100 percent efficacy and robust antibody response after vaccination with the COVID-19 Vaccine.

Topline results from an efficacy analysis on 12 to 15 year old participants through cases accrued by March 31, 2021 from the Phase 3 trial were recently announced. In this analysis, BNT162b2 was well tolerated with side effects generally consistent with those observed in participants 16 to 25 years of age. All participants in the trial will continue to be monitored for long-term protection and safety for an additional two years after their second dose.

These submissions represent a critical step in Pfizer’s and BioNTech’s ongoing efforts to support governments in broadening global vaccination efforts. The companies look forward to working closely with the U.S. Food and Drug Administration (FDA) and other worldwide regulatory authorities as part of the companies’ efforts to expand emergency or conditional authorization of their COVID-19 vaccine in 12- to 15-year-olds as quickly as possible.

The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States (jointly with Pfizer), United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at www.cvdvaccine-us.com.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

Coronavirus latest: India export ban leaves global jab supply far behind schedule, says Unicef

Before coronavirus arrived in the UK, only 3.8 per cent of the country’s 812,000 call centre workers were based at home, according to...

Covid-19 Live News Tracker: Global Updates on Vaccines and Cases

Here’s what you need to know:Dr. Rochelle P. Walensky during a Senate Health, Education, Labor and Pensions Committee hearing last week.Credit...Pool photo by...

Coronavirus US: death toll tops 160,000 as relief package impasse continues live updates

More than 6000 British Airways staff have accepted voluntary redundancy as the airline moves to tell thousands more cabin crew and ground staff whether...

Related Articles

Coronavirus latest: India export ban leaves global jab supply far behind schedule, says Unicef

Before coronavirus arrived in the UK, only 3.8 per cent of the country’s 812,000 call centre workers were based at home, according to...

Covid-19 Live News Tracker: Global Updates on Vaccines and Cases

Here’s what you need to know:Dr. Rochelle P. Walensky during a Senate Health, Education, Labor and Pensions Committee hearing last week.Credit...Pool photo by...

Coronavirus US: death toll tops 160,000 as relief package impasse continues live updates

More than 6000 British Airways staff have accepted voluntary redundancy as the airline moves to tell thousands more cabin crew and ground staff whether...